Sign In
Buy SPRC
$6.92
-0.0500 (-0.717%)
At Close: Jun 23, 2026
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
07:32am, Tuesday, 22'nd Jul 2025
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapi
SciSparc Announces 1-for-21 Reverse Share Split
05:03pm, Tuesday, 24'th Jun 2025
Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held Following the reverse share split, the Compa
SciSparc Announces Publication of Japanese Patent Application
07:32am, Tuesday, 27'th May 2025
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to
TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therap
SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers
08:25am, Monday, 03'rd Mar 2025
SciSparc will sell its MitoCareX's shares for $700,000 and exchange its remaining shares for common stock in N2OFF
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles
08:45am, Thursday, 27'th Feb 2025
TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapi
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
Impact Acquisition Enters Into Definitive Agreement to Complete Qualifying Transaction with Jeffs Brands and Fort Products
10:20am, Thursday, 06'th Feb 2025
February 6, 2025 – TheNewswire - Vancouver, British Columbia – Impact Acquisition Corp. (TSXV: IMPC.P) (“ Impact ”, the “ Company ” or the “ Resulting Issuer ”) is pleased to announce
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico
09:00am, Tuesday, 04'th Feb 2025
TEL AVIV, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
07:34am, Wednesday, 15'th Jan 2025
No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares TEL AVIV, Israel, Jan. 15, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles
08:41am, Monday, 13'th Jan 2025
TEL AVIV, Israel, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distr
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results
07:25am, Tuesday, 07'th Jan 2025
TEL AVIV, Israel, Jan. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?
11:04am, Monday, 06'th Jan 2025
On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.
TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
